Skip to main content

Advertisement

SpringerLink
Log in

Pharmacokinetics and neutrophil toxicity of paclitaxel orally administered in mice with recombinant interleukin-2

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Intrinsic P-glycoprotein (P-gp) expression in the gut limits paclitaxel uptake and, thus, its bioavailability when administered orally. Interleukin-2 has been reported to be a P-gp modulator in vitro and in vivo in mice. In the work described here, the effects of interleukin-2 pretreatment on pharmacokinetics and toxicity of paclitaxel orally administered were investigated.

Methods

For the pharmacokinetic study, 96 mice were allocated to two groups receiving either 10 mg/kg of paclitaxel by the oral route alone or 16.5 μg of human recombinant interleukin-2 (rIL2) by the intraperitoneal route twice daily for 3 days and then paclitaxel. Pharmacokinetic profiles were analysed first by the Bailer method, and then using a compartmental approach. For the toxicity study, 90 Swiss mice were allocated to three groups receiving paclitaxel (10 mg/kg orally), rIL2 alone (16.5 μg i.p. twice daily for 3 days, control group), or both treatments. Haematological parameters were measured and the three groups were compared using the Bailer method. A Bonferroni correction was applied to the test.

Results

A complex absorption of paclitaxel was revealed. The Bailer method showed that the mean area under the curve (AUC) values over 0–24 h were not significantly different in the two groups, despite a trend to reduced AUC in the pretreated group. The AUC over 0–0.5 h was significantly higher in the group pretreated with rIL2, but represented only a fraction of total exposure. These results were confirmed by the compartmental analysis. The elimination rate constant remained the same across both groups. rIL2 thus increased paclitaxel absorption for the 15 min following oral intake of the drug but did not enhance the overall exposure.

Conclusion

We found that a 3-day pretreatment with rIL2 had some in vivo inhibitory effects on P-gp activity for a short period after oral dosing of paclitaxel. Those results encourage further investigation of the effect of rIL2 on the overall exposure of paclitaxel. On the other hand, it seems that the joint administration of the two drugs did not increase the risk of myelosuppression, which might be worth knowing to treat advanced cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Bahadur N, Leathart JBS, Mutch E, Steimel-Crespi D, Dunn SD, Gilissen R, van Houdt J, Hendrickx J, Mannens G, Bohets H, Williams FM, Armstrong M, Crespi CL, Daly AK (2002) CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes. Biochem Pharmacol 64:1579

    Article  CAS  PubMed  Google Scholar 

  2. Bailer AJ (1988) Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 16:303

    CAS  PubMed  Google Scholar 

  3. Bonhomme-Faivre L, Pelloquin A, Tardivel S, Mathieu MC, Castagne V, Lacour B, Farinotti R (2002) Recombinant interleukin-2 treatment decreases P-glycoprotein activity and paclitaxel metabolism in mice. Anticancer Drugs 13:1

    Article  PubMed  Google Scholar 

  4. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevalier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187

    Google Scholar 

  5. Burtin P, Mentré F, van Bree J, Steimer JL (1996) Sparse sampling for assessment of drug exposure in toxicological studies. Eur J Drug Metab Pharmacokinet 21(2):105

    CAS  PubMed  Google Scholar 

  6. Cantoni L, Carelli A, Ghezzi P, Delgado R, Faggioni R, Rizzardini M (1995) Mechanisms of interleukin-2-induced depression of hepatic cytochrome P-450 in mice. Eur J Pharmacol 292:257

    CAS  PubMed  Google Scholar 

  7. Castagne V, Bonhomme Faivre L, Urien S, Reguiga MB, Soursac M, Gimenez F, Farinotti R (2004) Effect of recombinant interleukin-2 pretreatment on oral and intravenous digoxin pharmacokinetics and p-glycoprotein activity in mice. Drug Metab Dispos 32(2):168

    Article  CAS  PubMed  Google Scholar 

  8. Comets E, Mentré F, Kawai R, Nimerfall F, Marbach P, Vonderscher J (2000) Modelling the kinetics of release of octreotide from long-acting formulations injected intramuscularly in rabbits. J Pharm Sci 89:1123

    Article  CAS  Google Scholar 

  9. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA (2001) Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597

    Article  CAS  PubMed  Google Scholar 

  10. Demario MD, Ratain MJ (1998) Oral chemotherapy: rationale and future directions. J Clin Oncol 16:2557

    Google Scholar 

  11. Eiseman JL, Eddington ND, Leslie J, Mc Auley C, Sentz DL, Zuhowski M, Kujawa JM, Young D, Egorim MJ (1994) Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother Pharmacol 34:465

    Article  CAS  PubMed  Google Scholar 

  12. Friberg LE, Freijs A, Sandström M, Karlsson MO (2000) Semiphysiological model for the time course of leucocytes after varying schedules of 5-fluorouracil in rats. J Pharmacol Exp Ther 295:734

    CAS  PubMed  Google Scholar 

  13. Hing JP, Woolfrey SG, Greenslade D, Wright PM (2001) Analysis of toxicokinetic data using NONMEM: impact of quantification limit and replacement strategies for censored data. J Pharmacokinet Pharmacodyn 28:465

    Article  CAS  PubMed  Google Scholar 

  14. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, et al (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97:3473

    Article  CAS  PubMed  Google Scholar 

  15. Huet S, Bouvier A, Gruet MA, Jolivet E (1996) Statistical tools for nonlinear regression: a practical guide with S-Plus examples. Springer, New York

    Google Scholar 

  16. Huizing MT, Sewberath Misser VH, Pieters RC, ten Bokkel Huinink WW, Veenhof CHN, Vermorken JB, Pinedo HM, Beijnen JH (1995) Taxanes: a new class of antitumor agents. Cancer Invest 13:381

    CAS  PubMed  Google Scholar 

  17. Ihaka R, Gentleman R (1996) A language for data analysis and graphics. J Comput Graph Statist 5(3):299

    Google Scholar 

  18. Karlsson MO, Molnar V, Bergh J, Freijs A, Larsson R (1998) A general model for time-dissociated pharmacokinetic–pharmacodynamic relationship exemplified by paclitaxel myelosuppression. Clin Pharmacol Ther 63:11

    Google Scholar 

  19. Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, Mc Donald E, Kukulku MJ, Hsu A, Granneman GR, Baroldi PA, et al (1997) Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 41:654

    CAS  PubMed  Google Scholar 

  20. Liu G, Franssen E, Fitch MI, Warner E (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110

    Google Scholar 

  21. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA (1986) High-dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: responses, treatment-related morbidity and histological findings. JAMA 256:3117

    Article  CAS  PubMed  Google Scholar 

  22. Lum BL, Gosland MP (1995) MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol Oncol Clin North Am 9:319

    Google Scholar 

  23. Malingre MM, Beijnen JH, Schellens JHM (2001) Oral delivery of taxanes. Invest New Drugs 19:155

    Article  CAS  PubMed  Google Scholar 

  24. Malingre MM, Beijnen JH, Rosing H, Koopman FJ, Jewell RC, Paul EM, Ten Bokkel Huinink WW, Schellens JH (2001) Coadministration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer 84(1):42

    Article  Google Scholar 

  25. Meerum Terwogt JM, Schellens JHM, ten Bokkel Huinink WW, Beijnen JH (1999) Clinical pharmacology of anticancer agents in relation to formulations and administration routes. Cancer Treat Rev 25:83

    Article  PubMed  Google Scholar 

  26. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485

    CAS  PubMed  Google Scholar 

  27. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Marston Lirehan W, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2-alone. N Engl J Med 316:889

    CAS  PubMed  Google Scholar 

  28. Rowinsky EK, Donehower RC (1995) Paclitaxel (Taxol). N Engl J Med 332:1004

    Article  CAS  PubMed  Google Scholar 

  29. Salphati L, Benet LZ (1998) Effects of ketoconazole on digoxin absorption and disposition in rat. Pharmacology 56:308

    Article  CAS  PubMed  Google Scholar 

  30. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van der Valk MA, Robanus-Maandag EC, Te Riele HPJ, et al (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs. Cell 77:491

    Article  CAS  PubMed  Google Scholar 

  31. Schuetz EG, Beck WT, Schuetz JD (1996) Modulators and substrates of P-glycoprotein and cytochrome P4503A co-ordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 49:311

    CAS  PubMed  Google Scholar 

  32. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH (1996) Non linear murine pharmacokinetics of paclitaxel results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56:2112

    CAS  PubMed  Google Scholar 

  33. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DKF, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A 94:2031

    Article  CAS  PubMed  Google Scholar 

  34. Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, et al (1999) Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 59:1454

    CAS  PubMed  Google Scholar 

  35. Stein U, Wather W, Shoemaker RH (1996) Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance. Br J Cancer 74:1384

    CAS  PubMed  Google Scholar 

  36. Terao T, Hisagana E, Sai Y, Tamai I, Tsuji A (1996) Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol 48:1083

    CAS  PubMed  Google Scholar 

  37. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willigham MC (1987) Cellular localization of the multi-drug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 84:7735

    CAS  PubMed  Google Scholar 

  38. Van Asperen J, van Tellingen O, Sparreboom A, Schinkel AH, Borst P, Nooijen WJ, Beijnen JH (1997) Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 76:1181

    PubMed  Google Scholar 

  39. Van Asperen J, van Tellingen O, van der Valk MA, Rozenhart M, Beijnen JH (1998) Enhanced oral absorption and decreased elimination of paclitaxel in mice with cyclosporin A. Clin Cancer Res 4:2293

    Google Scholar 

  40. van Zuylen L, Verweij J, Sparreboom A (2001) Role of formulation vehicles in taxane pharmacology. Invest New Drugs 19:125

    Article  PubMed  Google Scholar 

  41. Veau C, Faivre L, Tardivel S, Soursac M, Banide H, Lacour B, Farinotti R (2002) Effect of Interleukin-2 on Intestinal P-glycoprotein expression and functionality in mice. J Pharmacol Exp Ther 302:742

    Article  CAS  PubMed  Google Scholar 

  42. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW (2001) No influence of the MDR-1 C3435 T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentration or rejection incidence in stable renal transplant recipients. Clin Chem 47:1048

    Google Scholar 

  43. Wacher VJ, Wu CY, Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129

    CAS  PubMed  Google Scholar 

  44. Wacher VJ, Salphati L, Benet LZ (1996) Active secretion and enterocystic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 20:99

    Article  CAS  Google Scholar 

  45. West WH, Tauer KW, Vannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK (1987) Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898

    CAS  PubMed  Google Scholar 

  46. Willey TA, Bekos EJ, Gaver R, Duncan GF, Tay LK, Beijnen JH, Farmen RH (1993) High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma. J Chromatogr 621:231

    Article  CAS  PubMed  Google Scholar 

  47. Woodcock DM, Jefferson S, Linsenmeijer ME, et al (1990) Reversal of multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 50:4199

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Jacques Ortega, and all the members of the Clinical Pharmacology Laboratory of Paul Brousse Hospital, for kindly helping with this project.

Author information

Authors and Affiliations

  1. Laboratoire de Pharmacologie, Service Pharmacie, Assistance Publique des Hôpitaux de Paris–Hôpital Paul Brousse, 14 avenue Paul Vaillant Couturier, 94800, Villejuif, France

    Candice Jamois & Laurence Bonhomme-Faivre

  2. Unité Propre de Recherche de l’Enseignement Supérieur 2706, Barrière et passage des médicaments, Faculté de Pharmacie de Chatenay Malabry, Université Paris XI, Paris, France

    Candice Jamois, Robert Farinotti & Laurence Bonhomme-Faivre

  3. INSERM E 0357, Département d’épidémiologie, biostatistiques  et recherche clinique, Assistance Publique des Hôpitaux de Paris–Hôpital Bichat-Claude-Bernard, 46 rue Henri Huchard, 75018, Paris, France

    Emmanuelle Comets & France Mentré

  4. Service d’Hématologie, Assistance Publique des Hôpitaux de Paris–Hôpital Paul Brousse, 14 avenue Paul Vaillant Couturier, 94800, Villejuif, France

    Sylvie Marion

  5. Service de Pharmacie Clinique et des Biomatériaux, Assistance Publique des Hôpitaux de Paris–Hôpital Bichat, 46 rue Henri Huchard, 75018, Paris, France

    Robert Farinotti

Authors
  1. Candice Jamois
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emmanuelle Comets
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. France Mentré
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sylvie Marion
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert Farinotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Laurence Bonhomme-Faivre
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laurence Bonhomme-Faivre.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jamois, C., Comets, E., Mentré, F. et al. Pharmacokinetics and neutrophil toxicity of paclitaxel orally administered in mice with recombinant interleukin-2. Cancer Chemother Pharmacol 55, 61–71 (2005). https://doi.org/10.1007/s00280-004-0824-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-004-0824-z

Keywords

Search

Navigation